Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Study limitation reported by the research below: “Trial was industry-funded by Novartis, which should be considered when interpreting reported outcomes.”